Alcanza And Reveles Join Forces To Expand Inclusive Clinical Research In Underrepresented Communities
Thursday, June 15, 2023
Alcanza Clinical Research, an investigator site network with a mission-driven approach, has announced a strategic partnership with Reveles, a provider of decentralized clinical trials focused on equity. Led by R'Kes D. Starling, CEO of Reveles, and Carlos Orantes, CEO of Alcanza, this collaboration aims to promote health equity by implementing next-generation hybrid decentralized models. The partnership will leverage decentralized tools and services, including in-home clinical trial support, direct-to-patient shipping, and technology enabling home-based participation. The objective is to reduce the barriers to clinical trial involvement in underrepresented and marginalized communities.
The collaboration specifically targets underrepresented Black and Brown communities in urban and mixed urban-rural areas, spanning locations such as Detroit, Michigan; central Virginia; the greater Charleston region in South Carolina; and the Dallas-Fort Worth metropolitan area in Texas. Reveles' CEO, R'Kes Starling, expressed enthusiasm about the partnership, stating, "Through our partnership with Alcanza, we can extend our comprehensive offering of eClinical technology, virtual site network, services, education, and engagement to the communities that need them the most. Alcanza, with its therapeutic expertise and operational knowledge, is the perfect partner for this mission."
The joint efforts of the two companies have already demonstrated promising outcomes. Reveles has successfully implemented decentralized clinical trial approaches in recent studies with Alcanza, providing support in staff augmentation, remote data entry, and pre-screening.
Carlos Orantes, CEO of Alcanza, expressed satisfaction with the partnership, saying, "We are thrilled to have chosen Reveles as our partner for recent initiatives. Our experience with their technology has been exceptional, laying a strong foundation for our strategic partnership."